Impact of bisphosphonate treatment on bone mineral density after kidney transplant

Table 1 Baseline clinical and biochemical characteristics of kidney transplant recipients who were treated with bisphosphonates and controls

	Study group (n = 35)	Control group (n = 27)	P value
Age in years (mean ± SD)	55.22 ± 10.99	53.44 ± 15.03	0.6
Gender (male/female)	20/15	19/8	NS
eGFR (mL/min/1.73 m2)	61.93 ± 15.8	59.9 ± 14.9	0.6
Time on dialysis (years ± SD)	6.22 ± 2.75	6.07 ± 3.02	NS
Cadaver donor	33	26	NS
Diabetes	8	6	NS
BMI (mean ± SD)	24.32 ± 3.91	25.29 ± 3.02	0.29
iPTH (ng/mL)	109.9 ± 102.5	107.7 ± 77.7	0.9
Baseline T score (mean ± SD)	-2.28 ± 1.06	-1.43 ± 1.13	0.0031
Follow-up (years ± SD)	3.78 ± 1.76	4.64 ± 2.96	NS

KTR: Kidney transplant recipients; eGFR: Epidermal growth factor receptor; BMI: Body mass index; iPTH: Intact parathormone; SD: Standard deviation.

Table 2 Impact of bisphosphonates or no treatment according to baseline bone mineral density

	Baseline T score	Follow-up T score	P value
Treated with bisphosphonates
BMD T score < -2.5 SD (n = 17)	-3.05 ± 0.4	-2.28 ± 0.54	< 0.0001
BMD T score > -2.5 SD (n = 18)	-1.58 ± 1	-1.08 ± 1.16	0.0069
Controls
BMD T score < -2.5 SD (n = 5)	-2.77 ± 0.38	-2.43 ± 0.64	0.26
BMD T score > -2.5 SD (n = 22)	-1.12 ± 1	-1.5 ± 0.8	0.049

BMD: Bone mineral density; SD: Standard deviation.

Table 3 Impact of bisphosphonates and no treatment on bone mineral density according to sex

	Baseline T score	Follow up T score	P value
Treated with bisphosphonates
Males (n = 20)	-2.3 ± 1.13	-1.8 ± 1.16	0.0026
Females (n = 15)	-2.26 ± 1.01	-1.48 ± 0.99	0.0001
Controls
Males (n = 19)	-1.45 ± 1.1	-1.64 ± 0.9	0.32
Females (n = 8)	-1.37 ± 1.2	-1.79 ± 0.72	0.38